Team 3 – STAFF – ACTUAL MEMBERS

“Welcome to Early stages of Parkinson’s disease”

MAP2/TGN-46/DAPI

Primary cortical neuron with staining for MAP2, TGN-46 and DAPI.

PPP2CA LRRK2

Primary cortical neuron with staining for PPP2CA and LRRK2.

CRISPR/Cas9

CRISPR/Cas9 technology used in the lab to silence or activate transcription in human cells: dCas9-mediated transcriptional modulation of phosphatases.
(A) dCas9 fused to effector domains can serve as an RNA-guided DNA-binding protein to target any protein to any DNA sequence. The effectors used with the catalytically inactive Cas9 (dCas9) are KRAB fusion protein to repress (CRISPRi) or the VP64 fusion protein to activate (CRISPRa) expression has shown on the picture.
(B) Stable suppression and overexpression of PPP1R1B by dCas9-KRAB or dCas9-VP64 in SH-SY5Y cells respectively. Cells stably expressing dCas9-KRAB or VP64 were infected with lentivirus constructs expressing a negative control sgRNA or two different sgRNAs targeting PPP1R1B.

Équipe Étapes précoces dans la maladie de Parkinson
You are here: Home > Early stages of Parkinson's disease > STAFF - ACTUAL MEMBERS

EARLY STAGES OF PARKINSON'S DISEASE

STAFF - ACTUAL MEMBERS

PhD STUDENTS

Antoine-Marchand

MARCHAND Antoine (D1)
LRRK2 and deficits of membrane trafficking in Parkinson’s disease.

Alessia-Sarchione

SARCHIOSE Alessia (D1)
Defect of membrane trafficking in Parkinson’s disease: role of Alpha-synuclein.

Elodie-Cuvelier

CUVELIER Élodie (D3)
Modulation of glucocerebrosidase activity in a transgenic mouse model overexpressing human alpha-synuclein.

Matthieu-Drouyer

DROUYER Matthieu (D3)
Validation of protein phosphatases that regulate the LRRK2 phosphorylation cycle.

Manelle-Sekfali

SEKFALI Manelle, Master 2

TECHNICAL STAFF

Coline-Leghay

LEGHAY Coline, PhD, Ingénieur de Recherche

Willian-Sibran

SIBRAN Willian, Ingénieur d’études

Laurine-Vandewynckel

VANDEWYNCKEL Laurine, Assistant Ingénieur

Melody-Phongphaisane

PHONGPHAISANE Melody, Technicienne

RESEARCHER

Helene-Carrie

CARRIE Hélène, PhD, PharmD, ATER